Concepedia

Author

Rosie Z. Yu

Ionis Pharmaceuticals (United States)ORCID

Also Known As

R Yu, R Z Yu, R. Yu, Rosie Yu, Rosie Z Yu, Rosie Z. Yu, Xiang Gao

87

Publications

7.4K

Citations

42

H-Index

64

Concepts

All Affiliations

Ionis Pharmaceuticals (United States)Amsterdam UMC Location University of AmsterdamUniversity of California San DiegoAkebia Therapeutics (United States)
RZ

About

Rosie Z. Yu is an author at Ionis Pharmaceuticals (United States) specializing in medicine, pharmacology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

21

2.6K

2

Biochemistry

6

6

490

3

Natural Sciences

3

3

252

4

Allergy

2

2

60

5

Engineering

1

1

136

Rosie Z. Yu

×

59

Publications

6.1K

Citations

40

H-Index

YearCitations

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Nicholas J. Viney, Julian C. van Capelleveen, Richard S. Geary,

The Lancet

2016

730

Cardiovascular and Metabolic Effects of <i>ANGPTL3</i> Antisense Oligonucleotides

Mark J. Graham, Richard Lee, Teresa Brandt,

New England Journal of Medicine

2017

567

Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B

John J.P. Kastelein, Mark K. Wedel, Brenda F. Baker,

Circulation

2006

356

Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis

Hong Zhang, Jesse D. Cook, Jeffrey C. Nickel,

Nature Biotechnology

2000

271

Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100

Rosie Z. Yu, Tae‐Won Kim, An Hong,

Drug Metabolism and Disposition

2006

236

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

Bruce Yacyshyn, W. Y. Chey, J S Goff,

Gut

2002

222

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia

Fatima Akdim, Maartje E. Visser, Diane L. Tribble,

The American Journal of Cardiology

2010

178

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Andrés Digenio, Richard L. Dunbar, Veronica J. Alexander,

Diabetes Care

2016

165

PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-α PHOSPHOROTHIOATE 2′-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES

Richard S. Geary, Rosie Z. Yu, Tanya Watanabe,

Drug Metabolism and Disposition

2003

162

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

Fatima Akdim, Erik S.G. Stroes, Eric J.G. Sijbrands,

Journal of the American College of Cardiology

2010

160

Page 1